FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1612-1617 June 15, 1995 Number 24 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Prior authorization — mandatory advance approval for the use of expensive medications — is now the primary method by which Medicaid programs control expenditures for drugs. However, whether this policy reduces expenditures for specific drugs without causing the unwanted substitution of other drugs or medical services has been largely unstudied. We evaluated the effects of a prior-authorization policy involving nongeneric nonsteroidal antiinflammatory drugs (NSAIDs) in the Medicaid program in Tennessee.

Methods We compared monthly Medicaid expenditures that were potentially affected by the policy change during the year before and the two years after its implementation. We studied prescriptions for NSAIDs, other analgesic or antiinflammatory drugs, and psychotropic drugs, as well as outpatient services and inpatient admissions for the management of pain or inflammation.

Results At the midpoint of the base-line year, 495,821 people were enrolled in Medicaid. During that year, mean annualized Medicaid expenditures for NSAID prescriptions amounted to $22.41. Expenditures decreased by 53 percent (95 percent confidence interval, 48 to 57 percent) during the next two years, for an estimated savings of $12.8 million. The reduction in expenditures resulted from the increased use of generic NSAIDs, as well as from a 19 percent decrease in overall NSAID use (95 percent confidence interval, 13 to 25 percent). There was no concomitant increase in Medicaid expenditures for other medical care. Regular users of nongeneric NSAIDs, those most affected by the policy change, had similar reductions in NSAID expenditures and use, with no increase in expenditures for other medical care.

Conclusions Prior-authorization requirements may be highly cost effective with regard to expenditures for NSAIDs, drugs that have very similar efficacy and safety but substantial variation in cost.

Source Information

From the Divisions of Gastroenterology (W.E.S.) and General Internal Medicine (M.R.G.), Department of Medicine, and the Department of Preventive Medicine (M.R.G., R.L.F., W.A.R.), Vanderbilt University School of Medicine; and the Tennessee State Department of Health, Bureau of TennCare (L.S.) — both in Nashville.

Address reprint requests to Dr. Smalley at the Department of Preventive Medicine, A-1124 MCN, Vanderbilt University School of Medicine, Nashville, TN 37232-2637.

Full Text of this Article

Related Letters:

Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Antiinflammatory Drugs
Lehmann D. F., Frey H. S., Smalley W. E., Griffin M. R., Ray W. A.
Extract | Full Text  
N Engl J Med 1995; 333:1289-1290, Nov 9, 1995. Correspondence

This article has been cited by other articles:

• West, J. C., Wilk, J. E., Rae, D. S., Muszynski, I. S., Stipec, M. R., Alter, C. L., Sanders, K. E., Crystal, S., Regier, D. A. (2009). Medicaid Prescription Drug Policies and Medication Access and Continuity: Findings From Ten States. Psychiatr. Serv. 60: 601-610 [Abstract] [Full Text]  
• Jackevicius, C. A., Tu, J. V., Demers, V., Melo, M., Cox, J., Rinfret, S., Kalavrouziotis, D., Johansen, H., Behlouli, H., Newman, A., Pilote, L. (2008). Cardiovascular Outcomes after a Change in Prescription Policy for Clopidogrel. NEJM 359: 1802-1810 [Abstract] [Full Text]  
• Johnson, T. J., Stahl-Moncada, S. (2008). Medicaid Prescription Formulary Restrictions and Arthritis Treatment Costs. Am. J. Public Health 98: 1300-1305 [Abstract] [Full Text]  
• Law, M. R., Ross-Degnan, D., Soumerai, S. B. (2008). Effect of Prior Authorization of Second-Generation Antipsychotic Agents on Pharmacy Utilization and Reimbursements. Psychiatr. Serv. 59: 540-546 [Abstract] [Full Text]  
• Soumerai, S. B., Zhang, F., Ross-Degnan, D., Ball, D. E., LeCates, R. F., Law, M. R., Hughes, T. E., Chapman, D., Adams, A. S. (2008). Use Of Atypical Antipsychotic Drugs For Schizophrenia In Maine Medicaid Following A Policy Change. Health Aff (Millwood) 27: w185-w195 [Abstract] [Full Text]  
• Wilk, J. E., West, J. C., Rae, D. S., Rubio-Stipec, M., Chen, J. J., Regier, D. A. (2008). Medicare Part D Prescription Drug Benefits and Administrative Burden in the Care of Dually Eligible Psychiatric Patients. Psychiatr. Serv. 59: 34-39 [Abstract] [Full Text]  
• Donohue, J. M., Frank, R. G. (2007). Estimating Medicare Part D's Impact on Medication Access Among Dually Eligible Beneficiaries With Mental Disorders. Psychiatr. Serv. 58: 1285-1291 [Abstract] [Full Text]  
• Goldman, D. P., Joyce, G. F., Zheng, Y. (2007). Prescription Drug Cost Sharing: Associations With Medication and Medical Utilization and Spending and Health. JAMA 298: 61-69 [Abstract] [Full Text]  
• West, J. C., Wilk, J. E., Muszynski, I. L., Rae, D. S., Rubio-Stipec, M., Alter, C. L., Narrow, W. E., Regier, D. A. (2007). Medication Access and Continuity: The Experiences of Dual-Eligible Psychiatric Patients During the First 4 Months of the Medicare Prescription Drug Benefit. Am. J. Psychiatry 164: 789-796 [Abstract] [Full Text]  
• Polinski, J. M., Wang, P. S., Fischer, M. A. (2007). Medicaid's Prior Authorization Program And Access To Atypical Antipsychotic Medications. Health Aff (Millwood) 26: 750-760 [Abstract] [Full Text]  
• Fischer, M. A., Choudhry, N. K., Winkelmayer, W. C. (2007). Impact Of Medicaid Prior Authorization On Angiotensin-Receptor Blockers: Can Policy Promote Rational Prescribing?. Health Aff (Millwood) 26: 800-807 [Abstract] [Full Text]  
• Huskamp, H. A., Stevenson, D. G., Donohue, J. M., Newhouse, J. P., Keating, N. L. (2007). Economic Grand Rounds: Coverage and Prior Authorization of Psychotropic Drugs Under Medicare Part D. Psychiatr. Serv. 58: 308-310 [Abstract] [Full Text]  
• Lin, S.-J., Kuo, S.-C., Yang, Y.-H. K. (2006). Appeals System and Its Outcomes in National Health Insurance in Taiwan. The Annals of Pharmacotherapy 40: 506-511 [Abstract] [Full Text]  
• Lipton, H. L., Agnew, J. D., Stebbins, M. R., Kuo, A., Dudley, R. A. (2005). Managing the Unmanageable: The Nature and Impact of Drug Risk in Physician Groups. Journal of Health Politics, Policy and Law 30: 719-750 [Abstract]  
• Fischer, M. A., Schneeweiss, S., Avorn, J., Solomon, D. H. (2004). Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors. NEJM 351: 2187-2194 [Abstract] [Full Text]  
• Poehling, K. A., Lafleur, B. J., Szilagyi, P. G., Edwards, K. M., Mitchel, E., Barth, R., Schwartz, B., Griffin, M. R. (2004). Population-Based Impact of Pneumococcal Conjugate Vaccine in Young Children. Pediatrics 114: 755-761 [Abstract] [Full Text]  
• Soumerai, S. B. (2004). Benefits And Risks Of Increasing Restrictions On Access To Costly Drugs In Medicaid. Health Aff (Millwood) 23: 135-146 [Abstract] [Full Text]  
• Malkin, J. D., Goldman, D. P., Joyce, G. F. (2004). The Changing Face Of Pharmacy Benefit Design. Health Aff (Millwood) 23: 194-199 [Abstract] [Full Text]  
• Soumerai, S. B., Adams, A. S., Mills, P. (2003). Evidence Needed Before Action. Health Aff (Millwood) 22: 261-263 [Full Text]  
• Flynn, K. E., Smith, M. A., Davis, M. K. (2002). From Physician to Consumer: The Effectiveness of Strategies to Manage Health Care Utilization. Med Care Res Rev 59: 455-481 [Abstract]  
• Kozyrskyj, A. L., Mustard, C. A., Cheang, M. S., Simons, F. (2001). Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma. CMAJ 165: 897-902 [Abstract] [Full Text]  
• Jones, D. L., Kroenke, K., Landry, F. J., Tomich, D. J., Ferrel, R. J. (1996). Cost Savings Using a Stepped-Care Prescribing Protocol for Nonsteroidal Anti-inflammatory Drugs. JAMA 275: 926-930 [Abstract]  
• Lehmann, D. F., Frey, H. S., Smalley, W. E., Griffin, M. R., Ray, W. A. (1995). Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Antiinflammatory Drugs. NEJM 333: 1289-1290 [Full Text]  
• Soumerai, S. B., Lipton, H. L. (1995). Computer-Based Drug-Utilization Review -- Risk, Benefit, or Boondoggle?. NEJM 332: 1641-1645 [Full Text]